

REFERENCES

- **Adams J, Franks S, Polson DW, et al:** Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. *Lancet* 1985; (2):1375–1379.
- **Adams J, Polson D W and Franks S :** Prevalence of Polycystic ovaries in women with anovulation and idiopathic hirsutism. *Br. Med. J.* 1986 ;(293):355-359.
- **Adams J, Reginald PW, Franks S, et al :** Uterine size ,endometrial thickness and the significance of cystic ovaries in women with pelvic pain due to congestion. *Br J Obstet Gynaecol* 1990; 97:583–7.
- **Adams JM, Taylor AE, Crowley WF, et al :** Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. *J Clin Endocrinol Metab* 2004; (89):4343–50.
- **Androgen Excess Society(AES):** Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess Society. Position statement: The Androgen Excess Society evidence-based criteria for defining the polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. *J Clin Endocrinol Metab* 2006; (91): 9237–9245.
- **Agrawal R, Sladkevicius P, Engman L, et al. :** Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. *Hum Reprod*;1998: 13:651–5.

- **Aleem FA and Predanic M.** : Transvaginal color Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease. *Fertil Steril* 1996; (65):510–516.
- **Allemand MC, Tummon IS, Phy JL, et al** : Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. *Fertil Steril* 2006; 85,214–219.
- **American Association Of Clinical Endocrinologists** : American Association Of Clinical Endocrinologists position statement on metabolic and cardiovascular sequences of polycystic ovary syndrome. *Endocr. Pract.* 2005;11(2):125-134.
- **Amso NN, Watermeyer SR, Pugh N, et al.**: Quantification of power Doppler energy and its future potential. *Fertil Steril* 2001; 76: 583-587.
- **Atiomo WU, Pearson S, Shaw S, et al.** : Ultrasound criteria in the diagnosis of polycystic ovary syndrome. *Ultrasound Med Biol*;2000: 26:977–80.
- **Azziz R, Hincapie LA, Knochenhauer ES, et al**: Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. *Fertil Steril* 1994; 72:915–25.
- **Azziz R, Sanchez LA, Knochenhauer ES, et al** : Androgen excess in women: experience with over 1000 consecutive patients. *J Clin Endocrinol Metab* 2004; 89:453–462.
- **Azziz R, Woods KS, Reyna R, et al** : The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004; 89:2745–2749.

- **Azziz R, Carmina E, Dewailly D, et al** : Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab* 2006; 91:4237–45.
- **Azziz R** : Definition, Diagnosis, and Epidemiology of the Polycystic Ovary Syndrome; In *The polycystic ovary syndrome current concepts on pathogenesis and clinical care* 2007;1:11.
- **Azziz R** :Strategies for Ovulation Induction in the Management of Anovulatory Polycystic Ovary Syndrome. In *The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care*. 2007; 99:116.
- **Azziz R, Dewailly D, Owerbach D, et al** : Clinical review 56: non classic adrenal hyperplasia: current concepts. *J Clin Endocrinol Metab* 2007 ; 78:810–5.
- **Baba K and Satoh K** : Development of the system for ultrasonic Fetal three-dimensional reconstruction. *Acta Obst Gynaec Jpn* 1986; 38-1385.
- **Baba K ,Okai T, Kozuma S, et al**: Real –time processable three-dimensional fetal ultrasound. *Lancet*,1996; 348,1307.
- **Baba K** : Basis and principles of three-dimensional ultrasound. In :**Takeuchi H, Baba K, IO Y** (eds). *Three-dimensional ultrasound in obstetrics and gynecology*. Tokyo, Japan. 2004; 12-29.
- **Baillargeon, J.P. and A. Carpentier**: Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. *Fertil Steril* ;2007, 88(4): 886-93.

- **Balen AH, Conway GS, Kaltsas G, et al:** Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. *Hum Reprod* 1995; 8:2107–11.
- **Balen AH :** Pathogenesis of polycystic ovary syndrome—the enigma unravels? *Lancet* :1999; 354,966–967.
- **Balen A, Michelmores K:** What is polycystic ovary syndrome ? Are national reviews important ? *Hum Reprod*,2002;17:2219.
- **Balen AH, Laven JS, Tan SL, et al :** Ultrasound assessment of the polycystic ovary: international consensus definitions. *Hum Reprod Update* 2003; 9,505–514.
- **Barbieri RL, Makris A, Randall RW, et al :** Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. *J Clin Endocrinol Metab* 1986; 62:904–10.
- **Battaglia C, Artini P G, D'Ambrogio G,et al:** The role of color Doppler imaging in the diagnosis of polycystic ovarian syndrome. *Am.J. Obstet. Gynecol.* 1995;172:108 -13.
- **Bonilla-Musoles F, Raga F and Osborne NG :**Three-dimensional ultrasound evaluation of ovarian masses. *Gynecol Oncol*,1996; 59,129–135.
- **Brinkley JF, McCallum WD, Muramatsu SK, et al:**Fetal weight estimation from ultrasonic three- dimensional head and Trunk reconstructions, evaluation in vitro. *Am J Obstet Gynecol* 1982; 144-715-21.
- **Breteche J :**Kyster ovariques et ovarites sclerocystique dans la sterilité Bull.Fed. *Gynecol.Obstet.*1992; 4:149-155.

- **Carmina E , Wong L and Chang L** : Endocrine abnormality in ovulatory women with Polycystic ovaries on ultrasound. *Hum.Reprod.*1999;12:905-9.
- **Casper RF, Mitwally MFM** : Aromatase inhibitors for ovulation induction. *J Clin Endocrinol Metab* ;2006, 91:760–71.
- **Chang R J and Katz S E** : Diagnosis of polycystic ovarian syndrome. *Endocrinol. Metab. Clin. North.Am.* 1999;28 (2):397-408.
- **Ciampelli M,Gtido M, Cucinelli F,et al**: Hypothalamic- pituitary-adrenal axis sensitivity to opioids in women with polycystic ovary syndrome . *Fertil Steril*;2000,73(4):712-7.
- **Clayton R N, Odgen V and Hodgkinson J**: How common are polycystic ovaries in normal women and what their significance for the fertility of the population is. *Clin.Endocrinol.*1992;37:127-34.
- **Clark AM, Ledger W, Galletly C, et al** : Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Human Reprod* .1995; 10:2705–12.
- **Clark AM, Thornley B, Tomlinson L, et al** : Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.*Hum Reprod.* 1998; 13:1502–5.
- **Conway GS, Honour JW, Jacobs HS,et al** : Heterogeneity of the polycystic ovary syndrome: clinical, endocrine, and ultrasound features in 556 patients. *Clin Endocrinol* .1989;30:459–470.
- **Conway GS** : Insulin resistance and the polycystic ovary syndrome. *Obstet Gynaecol*, 1990; 2:34–9.
- **DePriest PD, van Nagell JRJ, Gallion HH, et al**:Ovarian cancer screening in asymptomatic postmenopausal women. *Gynecol Oncol* 1993;(51):205–209.

- **Deslypere JP, Verdonck L, Vermeulen A, et al** : Fat tissue: a steroid reservoir and site of steroid metabolism. *J Clin Endocrinol Metab*,1985; 61:564-570.
- **DeUgarte CM, Woods KS, Bartolucci AA, et al**:Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. *J Clin Endocrinol Metab*, 2006; 91:1345–1350.
- **Dickey RP** : Doppler ultrasound investigation of uterine and ovarian blood flow in infertility and early pregnancy. *Hum Reprod Update*;1997, 3,467–503.
- **Dolz M, Osborne NG, Blanes J, et al.** : Polycystic ovarian three-dimensional ultrasonography. *J ultrasound Med*,1999;18,303–313.
- **Dunaif A, Segal KR, Shelley DR, et al** : Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. *Diabetes*,1992; 41:1257–66.
- **Dunaif A, Finegood DT** : Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. *J Clin Endocrinol Metab*,1996;81:942–7.
- **Dunaif A** : Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* ,1997; 18:774–800.
- **Edman CD & MacDonald PC** : Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory an anovulatory young women. *Am J Obstet Gynecol*,1978; 130:456-461.
- **Ehrmann DA, Barnes RB, Rosenfield RL, et al** : Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care*,1999; 22:141–6.

- **Ehrmann DA.:** Medical progress: polycystic ovary syndrome *N Engl J Med.* 2005;352(12):1223-1236.
- **ESHRE;** Female infertility: treatment options for complicated cases. The ESHRE Capri Workshop. *Hum Reprod*, 1997; 12:1191–6.
- **Evron S, Navot D and Lanfer N :** Induction of ovulation with combined human gonadotropins and dexamethazone in women with PCOD. *Fertil. Steril*;1983, 40: 183-186.
- **Farquhar CM, Birdsall M, Manning P, et al :** The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. *Aust NZ J Obstet Gynaecol*,1994; 34:6772.
- **Ferriman D & Gallwey JD :** Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab*,1961; 21: 1440-1447.
- **Fleischer AC, Andreotti RF:** Color Doppler sonography in obstetrics and gynecology. *Med Devices*; 2005,(5):606-611.
- **Fleming JEE, Spencer IH, Nicolson M,et al:** Medical ultrasound—germination and growth. In: **Baxter GM, Allan PL, Morley P**, (ed.). *Clinical diagnostic ultrasound* (2nd ed). Oxford, UK: 1999; 1–17.
- **Flier JS, Eastman RC, Minaker KL, et al :** Acanthosis nigricans in obese women with hyperandrogenism: characterization of an insulin-resistant state distinct from the type A and B syndromes. *Diabetes*,1985; 34:101–7.
- **Fox R :** Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. *Aust NZ J Obstet Gynaecol*,1999; 39:63–8.
- **Franks S.** Polycystic ovary syndrome. *N Engl J Med* 1995;333;853-861.

- **Franks J, Ghararii N and Water worth D** : The genetic basis of polycystic ovary syndrome. *Hum. Reprod* 1997, 12:2641-2648.
- **Franks S** : Candidate genes in women with polycystic ovary syndrome. *Fertil Steril* .2006;86:515.
- **Fruzzetti F, de Lorenzo D , Parrini D ,et al** : Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. *J Clin Endocrinol Metab* ;1994, 79 (3)831.
- **Futterweit W** : Polycystic ovary syndrome,clinical perspective and management. *Obstet. Gynecol.*;1999,54;402-413.
- **Gharani N, Waterworth DM, Bathy S, et al** : Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. *Hum Mol Genet*,1997; 6:397-402.
- **Gilja OH, Hausken T, Berstad A, et al**:Measurements of organ volume by ultrasonography. *Proc Inst Mech Eng.* 1999; 213:247–259.
- **Gilling- Smith C and Franks S** : Polycystic ovary syndrome. *Reprod. Med.Rev.* 2;1993.215-32.
- **Goldhieber JW & Green JA** : The polycystic ovary-clinical and histological features. *J Clin Endocrinol Metab* 1962;22:325–8.
- **Goldhieber JW**:Polycystic ovarian disease. *Fertil.Steril*,1981;35:371.
- **Goodarzi MO** : Genetics of PCOS. The polycystic ovary syndrome. Current concepts on Pathogenesis and clinical care 2007; 29-40.
- **Grodstein F, Goldman MB, Cramer DW**: Body mass index and ovulatory infertility. *Epidemiology*; 1994, 5:247–50.
- **Guzick DS** : Polycystiv ovary syndrome. *Obstet Gynecol* .2004; 103(1):181-193.

- **Hall JE, Taylor AE, Hayes FJ, et al** : Insights into hypothalamic–pituitary dysfunction in polycystic ovary syndrome. *J Endocrinol Invest*,1998; 21:602–11.
- **Hamilton-Fairley D, Kiddy DS, Watson H, et al** : Association of moderate obesity with poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotropins. *Br J Obstet Gynaecol*;1992, 99:128–31.
- **Hahn S, Tan S, Elsenbruch S, et al**: Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. *Horm Metab Res*; 2005, 37: 438–444.
- **Hatch R, Rosenfield RL, Kim MH, et al**: Hirsutism implications, etiology, and management. *Am J Obstet Gynecol*;1981 140:815–830.
- **Hill KM**: Update the diagnosis and treatment of PCOS, *Nurse Pract*. 2003;28:8-25.
- **Hoffman DI, Klove K, Lobo RA** : The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. *Fertil Steril* 1984; 42:76-81.
- **Huang I, Gibson M , Peterson CM,et al** : Hyperandrogenism and polycystic ovary syndrome. In: **Novak's Gynecology: Jonathan S. Berek(ed.)**.Lippincott Williams & Wilkins, (14th Ed.) ,2007;1073:1136.
- **Huber-Buchholz MM , Carey DG, Norman RJ,et al** : Restoration of reproductive potential by life style modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. *J Clin Endocrinol metab*;1999,84:1470.

- **Ingraham HA et al.:** Autocrine and paracrine Mullerian inhibiting substance hormone signaling in reproduction. *Recent Prog Horm Res* 2000; 55: 53-67.
- **Jakimiuk AJ, Weitsman SR, Brzechffa PR, et al:** Aromatase mRNA expression in individual follicles from polycystic ovaries. *Mol Hum Reprod*,1998; 41:1–8
- **Jakimiuk AJ et al :** Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. *J Clin Endocrinol Metab* ,2001; 86(3): 1318-23.
- **Jarvela IY, Mason HD, Sladkevicius P ,et al. :** Characterization of normal and polycystic ovaries using three-dimensional power Doppler ultrasonography. *J Assist Reprod Genet* ;2002 :19,582–590.
- **Jarvela IY, Sladkevicius P, Kelly S, et al. :** Quantification of ovarian power Doppler signal with three-dimensional ultrasonography to predict response during in vitro fertilization. *Obstet Gynecol* ;2003: 102,816–822.
- **Jokubkiene L, Sladkeviciusl P, Rovas L ,et al:** Assessment of changes in volume and vascularity of the ovaries during the normal menstrual cycle using threedimensional power Doppler ultrasound. *Hum Reprod* ;2006: 21 (10); 2661–2668.
- **Jonard S, Robert Y, Cortet-Rudelli C, et al.:** Ultrasound examination of polycystic ovaries: is it worth counting the follicles? *Hum Reprod* .2003: 18,598–603.
- **Jonard S and D. Dewailly:** The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main

- culprit for the follicular arrest. *Hum Reprod Update*,2004; 10(2): 107-17.
- **Kazer R** : Current concepts in polycystic ovary syndrome.In: **Rock J A, Faro S, Gant N F, Horowitz I R and Murpliy AA** (ed.) :Advances in Obstetrics and Gynecology (Vol. 20), Chicago Illinois),1995; 199-218.
 - **Kiddy DS, Hamilton-Fairley D, Bush A, et al:** Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. *Clin Endocrinol* ,1992; 36:105–11.
 - **Knight PG and Glistner C** : TGF-beta superfamily members and ovarian follicle development. *Hum Reprod*,2006; 132(2): 191-206.
 - **Kolodziejczyk** :Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. *Fertil Steril* ;2000, 73(6): 1149-54.
 - **Kurjak , Kupesic S, Schulman H, et al:**Transvaginal color flow Doppler in the assessment of ovarian and uterine blood flow in infertile women. *Fertil Steril*. 1999;56:870-4.
 - **Kyei-Mensah AA, LinTan S, Zaidi J, et al:** Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. *Hum Reprod* 1998; (13):1437–1441.
 - **Lakhani K, Seifalian M, Atiomo U, et al:** Polycystic ovaries, *Br J of Radiol*. 2002; 75, 9–16.
 - **Lam PM, Raine-fenning N:** The role of three-dimensional ultrasonography in polycystic ovary syndrome.*Hum Reprod* .2006;21(9):2209-2215.

- **Lam PM, Raine-fenning N:** The role of three-dimensional ultrasonography in polycystic ovary syndrome. *Ultrasound Obstet Gynecol*.2009;34(2):196-200.
- **Legro RS, Kusanman AR, Dodson WC, et al:**Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome:a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab*,1999; 84:165–9.
- **Legro RS, Bentley-Lewis R, Driscoll D, et al :** Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. *J Clin Endocrinol Metab*,2002;87:2128-33.
- **Legro RS :** Diagnostic criteria in polycystic ovary syndrome.*Semin Reprod Med* ;2003,21:267-75.
- **Legro RS ,Gnatuk CL, Kusanman AR, et al:** Clinical evaluation of polycystic ovary syndrome.*J Clin Endocrinol Metab* .2007;90:3236.
- **Loumaye E :** Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. *Hum Reprod*.2003, 18(2): 314-22.
- **Lobo RA. :** The role of the adrenal in polycystic ovary syndrome. *Semin Reprod Endocrinol*, 1985; 251-264.
- **Lobo RA.:** Hirsutism in polycystic ovary syndrome: current concepts. *Clin Obstet Gynecol* ,1991; 34:817-826.
- **Merz E :** Three-dimensional transvaginal ultrasound in gynecological diagnosis. *Ultrasound Obstet Gynecol* ;1999: 14,81– 86.

- **Michelmore KF, Balen AH, Dunger DB, et al.** : Polycystic ovaries and associated clinical and biochemical features in young women. *Clin Endocrinol*;1999, 51:779–786.
- **Munir I** :Insulin augmentation of 17alpha-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase in human ovarian theca cells. *Endocrinology*.2004; 145(1): 175-83.
- **National Institute for Clinical Excellence** : Fertility Assessment and Treatment for People with Fertility Problems. A Clinical Guideline. London: *RCOG Press*,2004.
- **Nelson TR, Pretorius DH** : The Doppler signal: where does it come from and what does it mean? *Am J Roentgenol*. 1988; 151: 439–447.
- **Nelson TR, Pretorius DH, Hagan-Ansert S ,et al**: Fetal heart assessment using three-dimensional ultrasound. *J Ultrasound Med*; 1999, 14:S30.
- **Ng EH, Chan CC, Yeung WS ,et al** : Comparison of ovarian stromal blood flow between fertile women with normal ovaries and infertile women with polycystic ovary syndrome. *Hum Reprod* ;2005: 20,1881–1886.
- **Ng EH, Chan CC and Ho PC** : Are there differences in ultrasound parameters between Chinese women with polycystic ovaries only and with polycystic ovary syndrome? *Eur J Obstet Gynecol Reprod Biol* ;2006: 125, 92–98.
- **Nikolaou D and Gilling-Smith C**: Early ovarian aging: are women with polycystic ovaries protected? *Hum Reprod*.2004,19(10): 2175-9.

- **Pache TD, Wladimiroff JW, Hop WC, et al:** How to discriminate between normal and polycystic ovaries: transvaginal US study. *Radiol*;1992: 183,421–423.
- **Pairleitner H, Steiner H, Hasenoehrl G, et al:** Three dimensional power Doppler sonography: imaging and quantifying blood flow and vascularization. *Ultrasound Obstet. Gynecol*.1999; 14, 139-143.
- **Pan HA, Wu MH, Cheng YC, et al:** Quantification of Doppler signal in polycystic ovarian syndrome using 3D power Doppler ultrasonography. *Hum Reprod*. 2002; 17:2484.
- **Polson DW, Adams J, Wadsworth J, et al :** Polycystic ovaries: a common finding in normal women. *Lancet*, 1988; 1:870–2.
- **Poretsky L :** The insulin-related ovarian regulatory system in health and disease. *Endocr Rev*;1999 . 20(4): 535-82.
- **Pretorius DH and Nelson TR :** Three-dimensional ultrasound. *Obstet, Gynecol*. 2001;5: 219-221.
- **Pritts EA :** Treatment of the infertile patients with polycystic ovarian syndrome. *Obstet Gynecol Surv*, 2002;57,587-597.
- **Pugeat M, Crave JC, Tourniaire J, et al :** Clinical and biochemical features of polycystic ovarian disease. *Fertil Steril*. 1963; 14:631–53.
- **Raine-Fenning NJ, Campbell BK, Collier J, et al:** The reproducibility of endometrial volume acquisition and measurement with the VOCAL-imaging program. *Ultrasound Obstet Gynecol* 2002; 19: 69–75.
- **Raine-Fenning NJ, Campbell BK, Clewes J, et al :** The interobserver reliability of ovarian volume measurement is improved with three-dimensional ultrasound, but dependent upon technique. *Ultrasound Med Biol*(2003a); 29, 1685–1690.

- **Raine-Fenning NJ, Campbell BK, Clewes JS,et al:** The reliability of virtual organ computer-aided analysis (VOCAL) for the semiquantification of ovarian, endometrial and subendometrial perfusion. *Ultrasound Obstet Gynecol*(2003b); 22:633–639.
- **Raine-Fenning NJ, Clewes JS, Kendall NR, et al :** The interobserver reliability and validity of volume calculation from three-dimensional ultrasound datasets in the in vitro setting. *Ultrasound Obstet Gynecol*(2003c); 21,283–291.
- **Raine-Fenning NJ, Campbell BK, Clewes JS,et al:** The interobserver reliability of three-dimensional power Doppler data acquisition within the female pelvis. *Ultrasound Obstet Gynecol* 2004; 23:501–508.
- **Raine-Fenning NJ, Lam PM:** Assessment of ovarian reserve using the inversion mode. *Ultrasound Obstet Gynecol*.2006;27:104-106.
- **Reaven G M:** Banting lecture ,role of insulin resistance in human diseases. *Diabetes*,1988;37:1595-1607.
- **Reaven G M:** Insulin and compensatory hyperinsulinemia, role in hypertension, dyslipidemia and coronary heart disease. *Am Heart J*,1991;121:1283-1288.
- **Riccabona M, Nelson TR and Pretorius DH :**Three-dimensional ultrasound: accuracy of distance and volume measurements. *Ultrasound Obstet Gynecol* ;1996: 7,429–434.
- **Riccabona M , Pretorius D H, Nelson T R, et al:** Three-dimensional ultrasound display modalities in obstetrics. *J. Clin. Ultrasound*.1997;(4):157-167.
- **Robert Y, Dubrulle F, Gaillandre L, et al:** Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation

- disorders: visual analysis versus computerized quantification. *Fertil Steril*; 1995, 64:307–12.
- **Roldan B, San Millan JL and Escobar- Morreale HF:** Genetic basis of metabolic abnormalities in Polycystic ovary syndrome: Implications for therapy. *Am J Pharmacogenomics*,2004;4:93-107.
 - **Rose PG:** Endometrial carcinoma. *N Engl J Med*.1996;335:640.
 - **Rosenfield RL :** Ovarian and adrenal function in polycystic ovary syndrome. *Endocrinol Metab Clin North Am*,1999 ; 28(2): 265-93.
 - **Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group :** Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004; 81:19–25.
 - **Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group:** Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Hum Reprod*. 2004; 19,41–47.
 - **Rubin JM, Bude RO, Carson PL, et al:** Power Doppler US: a potentially useful alternative to mean frequency based color Doppler US. *Radiol*. 1994; 190: 853–856.
 - **Schneider J, Bradlow HL, Strain G, et al. :** Effects of obesity on estradiol metabolism. *J Clin Endocrinol Metab*. 1983;56:973-978.
 - **Seino S, Seino M and Bell GI :** Human insulin receptor gene. *Diabetes*. 1990, 39: 129-33.
 - **Serafini P, Ablan F, Lobo RA,et al:** 5-alpha-Reductase activity in the genital skin of hirsute women. *J Clin Endocrinol Metab*.1985; 60:349-355.

- **Smith SK** : Regulation of angiogenesis in the endometrium. *Endocrinol Metab.* 2001; 12: 147–151.
- **Speroff L, Glass R H and Kase N G** : Anovulation. In: **Speroff L, Glass R H and Kase N G**(eds): Clinical Gynecologic Endocrinology and Infertility (5th ed). Baltimore, Williams and Wilkins Maryland.1994; 185 - 198.
- **Speroff L, Ease R H and Glass N G**:Anovulation.In: **Speroff L, Ease R H and Glass N G**: Clinical Gynecologic Endocrinology and Infertility. Baltimore, Lippincott, Williams and Wilkins. (6th ed).1999: 487-522.
- **Speroff L, Fritz M** :Hirsutisim.In: **Speroff L, Fritz M**(eds) :Clinical gynecologic endocrinology and infertility.(7th ed) Baltimore, Lippincott. Williman and Wilkins; 2005:523.
- **Stein IF** : Bilateral polycystic ovaries. *Am J Obstet Gynecol*,1964; 50:385–396.
- **Stein IF & Leventhal ML**: Amenorrhea associated with polycystic ovaries. *Am J Obstet Gynecol* ,1935; 29:181–91.
- **Swanson M, Sauerbrei EE, Cooperberg PL,et al** : Medical implications of ultrasonically detected polycystic ovaries. *J Clin Ultrasound*; 1981, 9:219–22.
- **Szilard J** : An improved three-dimensional display system. *Ultrasonics*: 1974; 76.273-76.
- **Tarkun I, Arslan BC,Canturk Z, et al**:Endometrial dysfunction in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.*2004;89:5592.
- **Taylor AE, McCourt B, Martin KA, et al** : Determinants of abnormal gonadotropin secretion in clinically defined women with

- polycystic ovary syndrome. *J Clin Endocrinol Metab*.1997; 82:2248–2256.
- **Trivax B and Azziz R** : Diagnosis of Polycystic Ovary Syndrome *Clin Obstet Gynecol*,2007; 50(1), 168–177.
 - **Urbanek M, Woodroffe A, Ewens KG,et al**: Cadidate gene region for polycystic ovary syndrome on chromosome 19p13.2. *J Clin Endocrinol Metab*,2005;90,6623.
 - **Van Hooff M H, Voohorst F J, Kaptein M B,et al**: Polycystic ovaries in adolescents and the relationship with menstrual cycle pattern, luteinizing hormone, androgens and insulin. *Fertil Steril* .2000;74:49-58.
 - **Webber LJ, Stubbs S, Stark J, et al**:Formation and early development of follicles in the polycystic ovary. *Lancet* ,2007; 362:1017–1021.
 - **Webber LJ et al** :Prolonged survival in culture of preantral follicles from polycystic ovaries. *J Clin Endocrinol Metab*,2007 ;92(5): 1975.
 - **Willis DS**: Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. *J Clin Endocrinol Metab*,1998;83(11): 3984-91.
 - **Wiesauer F**: Methodology of three- dimensional ultrasound . In: **Kurjak A, Kuspetic S**,(eds):Clinical application of four – dimensional sonography. Porthenon publishing, New York;2000:1-6.
 - **Zelevnik AJ, Little-Ihrig L, and Ramasawamy S** :Administration of dihydrotestosterone to rhesus monkeys inhibits gonadotropin-stimulated ovarian steroidogenesis. *J Clin Endocrinol Metab*,2004; 89(2): 860-6.

- **Yaman C, Ebner T, Jesacher K, et al:** Reproducibility of three-dimensional ultrasound endometrial volume measurements in patients with postmenopausal bleeding. *Ultrasound Obstet Gynecol.*2002;19(3):282-286.
- **Yildiz Bo, Yarali H ,Oguz H, et al:** Glucose intolerance, insulin resistance and hyperandrogenemia in first degree relatives of women with Polycystic ovary syndrome. *J Clin Endocrinol Metab*,2003;88.2031.